Can Nephrocheck™ Predict the Reversibility of Early, Acute Kidney Injury During Septic Shock?

Last updated: August 20, 2018
Sponsor: Centre Hospitalier Universitaire, Amiens
Overall Status: Active - Recruiting

Phase

N/A

Condition

Kidney Failure

Kidney Disease

Renal Failure

Treatment

N/A

Clinical Study ID

NCT02812784
PI2015_843_0022
  • Ages > 18
  • All Genders

Study Summary

Patients with septic shock in the intensive care unit have an elevated risk of developing acute kidney injury (AKI).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18 or over

  • Septic shock (according to Bone's criteria) within 4 hours of introduction ofcatecholamines

  • AKI, characterized by a KDIGO score ≥ 1

  • Social security coverage

Exclusion

Exclusion Criteria:

  • AKI requiring emergency RRT (in the critical care physician's opinion).

  • Anuria

  • Stage 4-5 chronic kidney failure with a GFR below 30 ml/min.

  • Rapidly progressing renal disorders (glomerulonephritis, HUS, blockage, etc.)

  • Obstructive AKI

  • Probable glomerular damage (nephritic syndrome, nephrotic syndrome, chronicglomerulonephritis)

  • Pregnancy or breastfeeding

  • Legal guardianship or lack of social security coverage.

  • Cardiocirculatory arrest

  • Life expectancy <48 hours.

  • Child C cirrhosis

  • Prior occurrence of AKI during the current hospital stay

  • Transplantation

  • Subject participating in another study with an exclusion period ongoing at the time ofthe pre-inclusion

Study Design

Total Participants: 190
Study Start date:
September 16, 2015
Estimated Completion Date:
August 31, 2018

Study Description

Patients with septic shock in the intensive care unit have an elevated risk of developing acute kidney injury (AKI). AKI is an independent factor for mortality. Interventions that limit the worsening of renal function might have an impact on the mortality rate in these patients. Given the absence of validated pharmacological treatments for limiting the progression of AKI or for accelerating recovery from AKI, early intervention and the restoration of the glomerular filtration rate (GFR) in this context of hemodynamic change during the initial phase of septic shock might improve the patients' prognosis. One major challenge is therefore how to determine whether or not the AKI is reversible. The best-studied biomarkers (NGAL and KIM 1) have little discriminant power in septic patients because of their poor specificity or unsuitable kinetics for very early diagnosis. The combination of urine assays for tissue inhibitor of metalloproteinase 2 (TIMP2) and insulin-like growth factor binding protein 7 (IGFBP7) has shown good diagnostic performance for the very early detection of the risk of developing AKI in the following 12 hrs. Urine levels of these two markers specifically reflect damage to kidney tubules. Moreover, the levels appear to be strongly correlated with the severity of tubule damage. Thus, one can reasonably hypothesize that measurement of these markers in the very early stages of septic shock might determine the presence and severity of kidney tubule damage. A threshold (yet to be defined) would help to differentiate between (i) transient, non-severe injury and (ii) injury that is already too severe to be reversible.

Connect with a study center

  • CHU Amiens

    Amiens, 80054
    France

    Active - Recruiting

  • CH Avranches-Granville

    Avranches, 50300
    France

    Active - Recruiting

  • CH Cahors

    Cahors, 46000
    France

    Active - Recruiting

  • CH Dax

    Dax, 40100
    France

    Active - Recruiting

  • CH Marc Jacquet

    Melun, 77000
    France

    Active - Recruiting

  • CH Princesse de Grace

    Monaco, 98000
    France

    Site Not Available

  • CH de Mont-de-Marsan

    Mont-de-Marsan, 40000
    France

    Active - Recruiting

  • CHU Montpellier

    Montpellier, 34172
    France

    Active - Recruiting

  • CH Paris-Saint Joseph

    Paris, 75
    France

    Active - Recruiting

  • CHU Poitiers

    Poitiers, 86000
    France

    Active - Recruiting

  • CHU Saint-Etienne

    Saint-Etienne, 42000
    France

    Active - Recruiting

  • CH Salon-de-provence

    Salon-de-provence, 13300
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.